Gilead Sciences Overview
- Year Founded
-
1987
- Status
-
Public
- Employees
-
17,600
- Stock Symbol
-
GILD
- Investments
-
71
- Share Price
-
$103.17
- (As of Friday Closing)
Gilead Sciences General Information
Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact Information
Website
www.gilead.comCorporate Office
- 333 Lakeside Drive
- Foster City, CA 94404
- United States
Corporate Office
- 333 Lakeside Drive
- Foster City, CA 94404
- United States
Gilead Sciences Timeline
Gilead Sciences Stock Performance
As of 25-Apr-2025, Gilead Sciences’s stock price is $103.17. Its current market cap is $132B with 1.25B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $103.17 | $106.15 | $62.07 - $119.96 | $132B | 1.25B | 9.4M | $4.78 |
Gilead Sciences Financials Summary
As of 31-Mar-2025, Gilead Sciences has a trailing 12-month revenue of $28.7B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 154,744,392 | 133,245,577 | 118,987,854 | 127,215,834 |
| Revenue | 28,734,000 | 28,754,000 | 27,116,000 | 27,281,000 |
| EBITDA | 7,672,000 | 4,153,000 | 10,120,000 | 8,746,000 |
| Net Income | 5,965,000 | 480,000 | 5,665,000 | 4,592,000 |
| Total Assets | 56,434,000 | 58,995,000 | 62,125,000 | 63,171,000 |
| Total Debt | 0 | 26,711,000 | 24,987,000 | 25,230,000 |
Gilead Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gilead Sciences Comparisons
Industry
Financing
Details
Gilead Sciences Competitors (27)
One of Gilead Sciences’s 27 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY |
Gilead Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Gilead Sciences Patents
Gilead Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250129051-A1 | Parp1 inhibitors and uses thereof | Pending | 23-Oct-2023 | ||
| US-20250122219-A1 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | Pending | 11-Oct-2023 | ||
| US-20250120989-A1 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | Pending | 11-Oct-2023 | ||
| US-20250127801-A1 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | Pending | 11-Oct-2023 | ||
| US-20250127989-A1 | Medical injections | Pending | 29-Sep-2023 | A61M5/2046 |
Gilead Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Gilead Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Gilead Sciences Investments & Acquisitions (71)
Gilead Sciences’s most recent deal was a Secondary Transaction - Open Market with Arcus Biosciences for . The deal was made on 21-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arcus Biosciences | 21-Feb-2025 | Secondary Transaction - Open Market | Biotechnology | ||
| Leo Pharma (Portfolio of Preclinical STAT6 Small Molecule Inhibitors in Ballerup, Denmark) | 10-Jan-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Aelix Therapeutics (HTI HIV Research Assets in Barcelona, Spain) | 25-Nov-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Leap Therapeutics | 15-Apr-2024 | PIPE | Biotechnology | ||
| CymaBay Therapeutics | 22-Mar-2024 | Merger/Acquisition | Biotechnology |
Gilead Sciences ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
21.68 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Gilead Sciences Exits (23)
Gilead Sciences’s most recent exit was on 21-Feb-2025 from Arcus Biosciences. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Arcus Biosciences | 21-Feb-2025 | Completed |
|
||
| Arcus Biosciences | 30-Jan-2024 | Completed |
|
||
| Gritstone bio | 24-Oct-2022 | Completed |
|
||
| Pardes Biosciences | 27-Dec-2021 | Completed |
|
||
| Gritstone bio | 17-Sep-2021 | PIPE | Completed |
|
Gilead Sciences Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kite Pharma | Santa Monica, CA | 2009 | |
| Myogen | Westminster, CO | 1996 | |
| Immunomedics | Morris Plains, NJ | 1982 |
Gilead Sciences FAQs
-
When was Gilead Sciences founded?
Gilead Sciences was founded in 1987.
-
Where is Gilead Sciences headquartered?
Gilead Sciences is headquartered in Foster City, CA.
-
What is the size of Gilead Sciences?
Gilead Sciences has 17,600 total employees.
-
What industry is Gilead Sciences in?
Gilead Sciences’s primary industry is Drug Discovery.
-
Is Gilead Sciences a private or public company?
Gilead Sciences is a Public company.
-
What is Gilead Sciences’s stock symbol?
The ticker symbol for Gilead Sciences is GILD.
-
What is the current stock price of Gilead Sciences?
As of 25-Apr-2025 the stock price of Gilead Sciences is $103.17.
-
What is the current market cap of Gilead Sciences?
The current market capitalization of Gilead Sciences is $132B.
-
What is Gilead Sciences’s current revenue?
The trailing twelve month revenue for Gilead Sciences is $28.7B.
-
Who are Gilead Sciences’s competitors?
Novartis, Amgen, AbbVie, Bristol-Myers Squibb, and Regeneron Pharmaceuticals are some of the 27 competitors of Gilead Sciences.
-
What is Gilead Sciences’s annual earnings per share (EPS)?
Gilead Sciences’s EPS for 12 months was $4.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
